Decoy Therapeutics Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
11
- Stock Symbol
-
DCOY
- Investments
-
3
- Share Price
-
$1.05
- (As of Thursday Closing)
Decoy Therapeutics General Information
Description
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
Contact Information
Website
www.decoytx.comCorporate Office
- 2450 Holcombe Boulevard
- Suite X
- Houston, TX 77021
- United States
Corporate Office
- 2450 Holcombe Boulevard
- Suite X
- Houston, TX 77021
- United States
Decoy Therapeutics Stock Performance
As of 12-Nov-2026, Decoy Therapeutics’s stock price is $1.05. Its current market cap is $2.52M with 2.39M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.05 | $1.09 | $0.90 - $16.92 | $2.52M | 2.39M | 2.16M | $12.74 |
Decoy Therapeutics Financials Summary
As of 30-Jun-2026, Decoy Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (3,996) | (1,006) | (304) | (4,562) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (14,592) | (12,607) | (5,730) | (12,885) |
| Net Income | (14,450) | (12,518) | (5,576) | (12,543) |
| Total Assets | 9,001 | 11,057 | 3,023 | 6,587 |
| Total Debt | 0 | 0 | 222 | 290 |
Decoy Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Decoy Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Decoy Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Decoy Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Decoy Therapeutics Investments & Acquisitions (3)
Decoy Therapeutics’s most recent deal was a Merger/Acquisition with Decoy Therapeutics (Merged). The deal was made on 13-Jan-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Decoy Therapeutics (Merged) | 13-Jan-2025 | Merger/Acquisition | Drug Discovery | ||
| DeuteRx (Oral, Small Molecule Targeted Protein Degradation Portfolio) | 13-Jan-2022 | Corporate Asset Purchase | Buildings and Property | ||
| Flex Pharma | 19-Jul-2019 | Merger/Acquisition | Drug Discovery |
Decoy Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 12, 2026
37.83 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Decoy Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Decoy Therapeutics (Merged) | Cambridge, MA | 2020 |
Decoy Therapeutics FAQs
-
When was Decoy Therapeutics founded?
Decoy Therapeutics was founded in 2011.
-
Where is Decoy Therapeutics headquartered?
Decoy Therapeutics is headquartered in Houston, TX.
-
What is the size of Decoy Therapeutics?
Decoy Therapeutics has 11 total employees.
-
What industry is Decoy Therapeutics in?
Decoy Therapeutics’s primary industry is Drug Discovery.
-
Is Decoy Therapeutics a private or public company?
Decoy Therapeutics is a Public company.
-
What is Decoy Therapeutics’s stock symbol?
The ticker symbol for Decoy Therapeutics is DCOY.
-
What is the current stock price of Decoy Therapeutics?
As of 12-Nov-2026 the stock price of Decoy Therapeutics is $1.05.
-
What is the current market cap of Decoy Therapeutics?
The current market capitalization of Decoy Therapeutics is $2.52M.
-
What is Decoy Therapeutics’s annual earnings per share (EPS)?
Decoy Therapeutics’s EPS for 12 months was $12.74.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
